Vera Therapeutics, Inc. 8-K

What Happened

• Vera Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on May 21, 2026 (record date March 24, 2026). At the meeting, shareholders elected three Class II directors — Michael M. Morrisey, Ph.D.; Patrick G. Enright; and James R. Meyers — each to serve until the 2029 Annual Meeting. Shareholders also ratified KPMG LLP as the company’s independent registered public accounting firm for fiscal 2026 and approved, on an advisory basis, the compensation of the company’s named executive officers.

Key Details

• Record date and shares outstanding: 71,713,905 shares of Class A common stock entitled to vote (as of March 24, 2026).
• Director election vote totals:
  • Michael M. Morrisey, Ph.D.: 45,288,710 for; 13,814,671 withheld; 2,863,469 broker non-votes.
  • Patrick G. Enright: 54,697,296 for; 4,406,085 withheld; 2,863,469 broker non-votes.
  • James R. Meyers: 58,946,269 for; 157,112 withheld; 2,863,469 broker non-votes.
• Auditor ratification (fiscal 2026): KPMG LLP — For: 61,834,842; Against: 44,710; Abstain: 87,298.
• Advisory "say-on-pay" result: Approved — For: 56,585,568; Against: 2,433,537; Abstain: 84,276; Broker non-votes: 2,863,469.

Why It Matters

• Board continuity: All three nominees were elected to full terms through 2029, confirming the board composition and governance continuity for investors.
• Audit firm stability: Ratification of KPMG LLP means the company will continue with its current independent auditor for 2026, which affects financial reporting and audit continuity.
• Executive pay endorsement: The advisory approval of executive compensation indicates shareholder support for the company’s named executive officers’ pay disclosures as presented in the proxy.